Preview

Pharmacogenetics and Pharmacogenomics

Advanced search

Modern approach personalization warfarin dosing: Where and how you can make a pharmacogenetic testing in Russia?

Abstract

Objective: To explore the Russian market commercial laboratories conducting pharmacogenetic testing for warfarin dosing personalization. Materials and methods. After the search the Internet using the Google search engine systems of laboratories and medical centers offering commercial pharmacogenetic testing for warfarin dosing personalization, conducted a survey of their information services. The results. Were compared with data from previously conducted a similar study conducted in 2010 (Gerasimova K. et al.). Significant differences were assessed using the Mann-Whitney test. Results. Compared with 2010, the number of commercial laboratories, performing pharmacogenetic testing for warfarin dosing increased personalization in Russia from 18 to 35. There is decrease in the cost of pharmacogenetic testing 6 018 [750; 14 000] to 2 395 rubles. [560; 11 880] (p<0.05). Also, reduce the period of pharmacogenetic test with 18 [5; 30] to 9 [3; 24] days (p<0.05). Conclusions. Compared with 2010, Russia increased availability perform pharmacogenetic testing for warfarin dosing personalization in commercial laboratories.

About the Authors

D. A. Sychev
RMAPE
Russian Federation

Department of Clinical Pharmacology and Therapeutics

Moscow



L. S. Kutuzova
Sechenov First MSMU
Russian Federation

Department of Economics of Pharmacy

119991, Moscow



L. B. Vas’kova
Sechenov First MSMU
Russian Federation

Department of Economics of Pharmacy

119991, Moscow



References

1. Михеева Ю.А., Кропачева Е.С., Игнатьев И.В., Сычев Д.А., Добровольский О.Б., Панченко Е.П. Полиморфизм гена цитохрома P4502C9 (CYP2C9) и безопасность терапии варфарином.// Кардиология. — 2008. — Том 48,N 3. — 52-57.

2. Сычев Д.А., Антонов И.М., Кропачева Е.С., Панченко Е.П. Какой из алгоритмов дозирования варфарина, основанных на результатах фармакогенетического тестирования, подходят российским пациентам?// Кардиология.- 2010.- №4.- с. 35-37.

3. Becquemont L., Alfirevic A., Amstutz U., Brauch H., Jacqz-Aigrain E., Laurent-Puig P., Molina M.A., Niemi M., Schwab M., Somogyi A.A., Thervet E., Maitland-van der Zee A.H., van Kuilenburg A.B., van Schaik R.H., Verstuyft C., Wadelius M., Daly A.K. Pharmacogenomics. Practical recommendations for pharmacogenomics-based prescription: 2010 ESF-UB Conference on Pharmacogenetics and Pharmacogenomics. 2010 Jan;12(1):113-24.

4. Сычев Д.А., Антонов И.М., Игнатьев И.В., Наумова Ю.В., Дмитриев В.А., Кропачева Е.С., Добровоский О.Б., Панченко Е.П., Ташенова А.И., Кукес В.Г. Антикоагулянтное действие и безопасность применения варфарина при его дозировании, основанном на результатах фармакогенетического тестирования: результаты первого российского проспективного исследования. // Кардиология — 2010.- №5.- с. 42-46.

5. Epstein R.S., Moyer T.P., Aubert R.E., O Kane D.J., Xia F., Verbrugge R.R., Gage B.F., Teagarden J.R. Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study). JAmCollCardiol. 2010 Jun 22;55(25):2804-12.

6. Mazur-Bialy A.I., Zdebska K., Wypasek E., Undas A. Repeated bleeding complications during therapy with vitamin K antagonists in a patient with the VKORC1*2A and the CYP2C9*3/*3 alleles: genetic testing to support switching to new oral anticoagulants.ThrombRes. 2013 Mar;131(3):279-80.

7. Диагностика и лечение фибрилляции предсердий. Рекомендации ВНОК и ВНОА. 2011. URL: http://rpcardio.ru/upload/archive/pdf_articles/2011/RFK_VNOK-2011-7_4.pdf

8. Герасимова К.В. Организационно-экономические аспекты внедрения фармакогенетического тестирования в практическое здравоохранение. Дисс… канд. мед. наук. М.; 2012.


Review

For citations:


Sychev D.A., Kutuzova L.S., Vas’kova L.B. Modern approach personalization warfarin dosing: Where and how you can make a pharmacogenetic testing in Russia? Pharmacogenetics and Pharmacogenomics. 2016;(1):24-28. (In Russ.)

Views: 1027


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2588-0527 (Print)
ISSN 2686-8849 (Online)